Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Onconephrology
What is your approach to re-challenging patients with immune checkpoint inhibitors whom developed predominately acute tubular injury without acute interstitial nephritis?
Related Questions
How would you approach management and monitoring of AL amyloidosis with isolated renal involvement?
Would you continue to monitor urinary protein levels and dose adjust axitinib in a patient with metastatic malignancy who is now dialysis dependent but has residual renal function?
Are there any special considerations you take with ESA use in hospitalized patients with ESKD who undergo stem cell transplantation?
Do you recommend holding ACE inhibitors, ARBs, and SGLT2 inhibitors for patients with chronic kidney disease and malignancy who are about to start high-dose intravenous methotrexate?
Do you postpone hemodialysis for a period of time after stem cell transplantation in a hospitalized patient with ESKD?
What is your approach to IV fluid management for the treatment of hypercalcemia of malignancy?
Do you have specific waiting periods before a patient can be listed for a kidney transplant if they have a past history of malignancy?
What is your approach to waiting period for an ESKD patient getting a kidney transplant after just being treated for bacteremia?
How do you determine when it is appropriate to transition a patient back to peritoneal dialysis after they were switched to hemodialysis due to PD catheter removal for refractory peritonitis, once the infection has been treated?
Are there instances when you recommend kidney stone disorder gene testing in patients suspected of having cystinuria?
